We take cancer personally

Your day-by-day guide to ASCO

May 31 – June 4, 2013

McCormick Place Convention Center
Chicago, IL, USA
<table>
<thead>
<tr>
<th>Product key</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDL</td>
<td>Anti-PDL1</td>
</tr>
<tr>
<td>B</td>
<td>Bevacizumab</td>
</tr>
<tr>
<td>C</td>
<td>Capecitabine</td>
</tr>
<tr>
<td>E</td>
<td>Erlotinib</td>
</tr>
<tr>
<td>GA</td>
<td>GA101</td>
</tr>
<tr>
<td>GDC</td>
<td>GDC-0199</td>
</tr>
<tr>
<td>P</td>
<td>Pertuzumab</td>
</tr>
<tr>
<td>R</td>
<td>Rituximab</td>
</tr>
<tr>
<td>T</td>
<td>Trastuzumab</td>
</tr>
<tr>
<td>Vem</td>
<td>Vemurafenib</td>
</tr>
<tr>
<td>Vis</td>
<td>Vismodegib</td>
</tr>
</tbody>
</table>
ORAL ABSTRACT SESSION

Genitourinary (Nonprostate) Cancer

Session time: 13:15 – 16:15  
Presentation time: 14:45 – 15:00  
Venue: E Arie Crown Theater

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). (Daniel C. Cho; Abstract # 4505)

Melanoma/Skin Cancers

Session time: 13:15 – 16:15  
Presentation time: 13:15 – 13:30  
Venue: S406

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial. (Philippa Corrie; Abstract # LBA9000)

Central Nervous System Tumors

Session time: 15:00 – 18:00  
Presentation time: 15:00 – 15:15  
Venue: E253

Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-nonmethylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial. (Ulrich Herrlinger; Abstract # LBA2000)

Session time: 15:00 – 18:00  
Presentation time: 15:15 – 15:30  
Venue: E253

A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. (Walter Taal; Abstract # 2001)
Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). (Wolfgang Wick; Abstract # 2002)

Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. (Terri S. Armstrong; Abstract # 2003)

Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). (Roger Henriksson; Abstract # 2005)

Gastrointestinal (Colorectal) Cancer

Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). (Miriam Koopman; Abstract # 3502)

FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. (Alfredo Falcone; Abstract # 3505)
POSTER DISCUSSION SESSION

Breast Cancer – HER2/ER

Session time: 08:00 – 12:00
Presentation time: 12:00 – 13:00
Venue: E450b
Venue: E Hall D1

Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial. (Evandro De Azambuja; Poster Board 13, Abstract # 525)

Leukemia, Myelodysplasia, and Transplantation

Session time: 08:00 – 12:00
Presentation time: 12:00 – 13:00
Venue: S405
Venue: S406

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia. (John F. Seymour; Poster Board 10, Abstract # 7018)

GENERAL POSTER SESSION

Lung cancer – Non-small Cell Metastatic

Session time: 08:00 – 11:45
Venue: S Hall A2

Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials. (Corey J. Langer; Poster Board 36E, Abstract # 8073)

Session time: 08:00 – 11:45
Venue: S Hall A2

Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN). (Benjamin Besse; Poster Board 34G, Abstract # 8059)
Erlotinib after initial platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR) wild-type (WT) non-small cell lung cancer (NSCLC): Results of a combined patient-level analysis of the BR.21 and SATURN trials. (Raymond U. Osarogiagbon; Poster Board 37D, Abstract # 8080)

Melanoma/Skin Cancers

Open-label, multicenter safety study of vemurafenib in patients with BRAF\textsuperscript{V600} mutation-positive metastatic melanoma. (James M. Larkin; Poster Board 45A, Abstract # 9046)

Central Nervous System Tumors

Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly diagnosed adult glioblastoma patients. (Martin K. Nicholas; Poster Board 5H, Abstract # 2076)

Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy

Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT. (Moshe J. Inbar; Poster Board 18G, Abstract # 1040)
A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial. (Antonio Llombart-Cussac; Poster Board 3B, Abstract # 555)

Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC). (Farrah M. Datko; Poster Board 9E, Abstract # 606)

Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab. (Eva Maria Ciruelos Gil; Poster Board 8G, Abstract # 600)
PLENARY SESSION
Including FDA Commissioner Address, Public Service Award, & Science of Oncology Award and Lecture

Session time: 13:00 – 16:20  Venue: N Hall B1
Presentation time: 13:50 – 14:05

RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). (Mark R. Gilbert; Abstract # 1)

Session time: 13:00 – 14:20  Venue: N Hall B1
Presentation time: 14:50 – 15:05

Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. (Krishnansu S. Tewari; Abstract # 3)

CLINICAL SCIENCE SYMPOSIUM
Predictive Molecular Biomarkers: Enriching Clinical Trial Populations for Gliomas

Session time: 08:00 – 09:30  Venue: E253
Presentation time: 08:30 – 08:45

Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). (Erik P. Sulman; Abstract # LBA2010)

PD1/PDL1: An Effective Target in Melanoma

Session time: 09:45 – 11:15  Venue: E Arie Crown Theater
Presentation time: 10:15 – 10:30

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). (Omid Hamid; Abstract # 9010)
Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. (Luca Gianni; Abstract # 503)

Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC). (Jyoti D. Patel; Poster Board 1, Abstract # 8012)

65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). (Wolfgang Schuette; Poster Board 2, Abstract # 8013)

Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial. (Achim Rittmeyer; Poster Board 3, Abstract # 8014)
Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C). (Tony Mok; Poster Board 10, Abstract # 8021)

**GENERAL POSTER SESSION**

**Gastrointestinal (Colorectal) Cancer**

Session time: 08:00 – 11:45  Venue: S Hall A2

**Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA.** (Thomas Gruenberger; Poster Board 11E, Abstract # 3619)

Session time: 08:00 – 11:45  Venue: S Hall A2

**Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study.** (Richard Greil; Poster Board 9F, Abstract # 3604)

Session time: 08:00 – 11:45  Venue: S Hall A2

**Quality of life (QOL) and toxicity among patients in CALGB 80405.** (Michelle J. Naughton; Poster Board 10E, Abstract # 3611)
CLINICAL SCIENCE SYMPOSIUM

Novel Targeted Therapies in Non-Hodgkin Lymphoma (eQ&A)

Session time: 11:30 – 13:00
Presentation time: 12:30 – 12:45
Venue: E354a


ORAL ABSTRACT SESSION

Lung Cancer – Non-small Cell Metastatic

Session time: 15:00 – 18:00
Presentation time: 16:15 – 16:30
Venue: E Hall D2

A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance pem plus bev versus paclitaxel (Pac) plus cb plus bev followed by maintenance bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results. (Mark A. Socinski; Abstract # 8004)

Session time: 15:00 – 18:00
Presentation time: 17:30 – 17:45
Venue: E Hall D2

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). (David R. Spigel; Abstract # 8008)
Developmental Therapeutics – Immunotherapy

Session time: 15:00 – 18:00
Presentation time: 15:00 – 15:15
Venue: S406

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. (Roy S. Herbst; Abstract # 3000)

Session time: 15:00 – 18:00
Presentation time: 15:15 – 15:30
Venue: S406

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. (John D. Powderly; Abstract # 3001)

POSTER DISCUSSION SESSION
Central Nervous System Tumors

Session time: 08:00 – 12:00
Presentation time: 11:30 – 12:30
Venue: E450a
Venue: E253

Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma. (Eudocia Q. Lee; Poster Board 2, Abstract # 2013)

Session time: 08:00 – 12:00
Presentation time: 11:30 – 12:30
Venue: E450a
Venue: E253

A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). (Kathryn M. Field; Poster Board 6, Abstract # 2017)

Session time: 08:00 – 12:00
Presentation time: 11:30 – 12:30
Venue: E450a
Venue: E253

BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. (Jeffrey J. Raizer; Poster Board 8, Abstract # 2019)
Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An Anocef phase II trial. (German Reyes-Botero; Poster Board 9, Abstract # 2020)

Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM). (Ryo Nishikawa; Poster Board 12, Abstract # 2023)

Melanoma/Skin Cancers

Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients. (Jean Jacques Grob; Poster Board 24, Abstract # 9036)

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study. (Aleksandar Sekulic; Poster Board 25, Abstract # 9037)
Efficacy and safety of front-line bevacizumab (BEV), weekly paclitaxel (wPAC), and q3w carboplatin (C) in elderly patients (pts) with ovarian cancer (OC): Subgroup analysis of OCTAVIA. (Antonio Gonzalez-Martin; Poster Board 44H, Abstract # 5544)

Feasibility and safety of front-line bevacizumab (BEV)-containing therapy after neoadjuvant (NA) chemotherapy (CT) for ovarian cancer (OC): The ROSiA experience. (Jacob Korach; Poster Board 44E, Abstract # 5541)

Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC). (Martin R. Stockler; Poster Board 44F, Abstract # 5542)
**ORAL ABSTRACT SESSION**

**Leukemia, Myelodysplasia, and Transplantation**

Session time: 08:00 – 11:00
Presentation time: 09:15 – 09:30
Venue: E354b

- Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. (Valentin Goede; Abstract # 7004)

**Lung Cancer – Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers**

Session time: 09:45 – 12:45
Presentation time: 11:45 – 12:00
Venue: E Hall D1

- Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup. (Jean-Charles Soria; Abstract # 7505)

**POSTER DISCUSSION SESSION**

**Gastrointestinal (Colorectal) Cancer**

Session time: 08:00 – 12:00
Presentation time: 11:30 – 12:30
Venue: S405

- FOLFIRI plus bevacizumab (bev) as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) who have failed first-line bev plus oxaliplatin-based therapy: The randomized phase III EAGLE study. (Hiroshi Tamagawa; Poster Board 8, Abstract # 3516)
Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer. (Mark P. Saunders; Poster Board 13, Abstract # 3521)
Lakeside Center
(East Building)

Level 2
Arie Crown Theater
Food Service
Business Center
Gift Shop

Level 2.5
Food Court/Restaurant
Gift Shop
Business Center
METRA Entrance

Level 2
Office

North Building

Legend

<table>
<thead>
<tr>
<th>Level</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Lakeside Ballroom E354</td>
</tr>
<tr>
<td>2</td>
<td>Halls D1 &amp; D2, Hall E</td>
</tr>
<tr>
<td>3</td>
<td>Offices, Halls B1 &amp; B2</td>
</tr>
<tr>
<td>4</td>
<td>Rooms E450-451, E300-303, E250-272</td>
</tr>
<tr>
<td>5</td>
<td>Rooms S501-526, S401-406</td>
</tr>
<tr>
<td>2.5</td>
<td>Grand Concourse</td>
</tr>
<tr>
<td>2.5</td>
<td>Hotel</td>
</tr>
</tbody>
</table>

Conference Center
(Rooms CC 10-CC 24)
& Parking Lot A

MARTIN LUTHER KING, JR. DRIVE

CERMACK ROAD
Chicago Marriott Downtown Magnificent Mile
540 N. Michigan Ave.
Chicago, IL, 60611
Tel: +1-312-836-0100
   Breakfast: Harvest Grill Restaurant, 2nd Floor
   06:30 – 11:00

Hilton Chicago
720 S. Michigan Ave.
Chicago, IL, 60605
Tel: +1-312-922-4400
   Breakfast: 720 South Bar & Grill
   Mon–Fri: 06:00 – 11:00
   Sat–Sun: 06:00 – 12:00

Swissôtel Chicago
323 E. Wacker Drive
Chicago, IL, 60601
Tel: +1-312-565-0565
   Breakfast: Restaurant Geneva + Lobby Bar & Lounge
   Mon–Fri: 06:30 – 10:30
   Sat–Sun: 06:30 – 12:00

The James Hotel Chicago
55 E. Ontario
Chicago, IL, 60611
Tel: +1-312-337-1000
   Breakfast: Great Room West
   06:30 – 08:30

The Palomar Chicago
505 N. State St.
Chicago, IL, 60654
Tel: +1-312-755-9703
   Breakfast: Sable Restaurant
   06:30 – 09:30
W Hotel Chicago – Lakeshore
644 N. Lake Shore Drive
Chicago, IL, 60611
Tel: +1-312-943-9200
Breakfast: Wave Restaurant
06:30 – 09:00

Hyatt Regency McCormick Place
2233 S. Dr. Martin Luther King Jr. Drive
Chicago, IL, 60616
Tel: +1-312-567-1234
Breakfast: Restaurant Shor
06:30 – 11:00

Inn of Chicago
162 E. Ohio St.
Chicago, IL, 60611
Tel: +1-312-787-3100
Breakfast: Harbor Room
07:00 – 09:00

Hilton Palmer House
17 E. Monroe St.
Chicago, IL, 60603
Tel: +1-312-726-7500
Breakfast: Lockwood Restaurant
06:30 – 11:00

Union League Club of Chicago
65 W. Jackson Blvd.
Chicago, IL, 60604
Tel: +1-312-427-7800
Breakfast: Wigwam, 3rd Floor
Mon–Fri: 06:30–11:00
Sat: 07:00 – 12:00
Sun: 07:00 – 14:00
Renaissance Blackstone Chicago
636 S. Michigan Ave.
Chicago, IL, 60605
Tel: +1-312-447-0955
  Breakfast: Mercat Restaurant
  Mon–Fri: 06:30 – 11:00
  Sat–Sun: 07:00 – 11:00

Congress Plaza Hotel Chicago
520 S. Michigan Ave.
Chicago, IL, 60605
Tel: +1-312-427-3800
  Breakfast: Gazebo Restaurant
  06:30 – 10:30